Thursday, October 15, 2026
21.7 C
Bengaluru

Anup Soans

Reach out to Anup Soans: anupsoans@medicinman.net.

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy, mergers and acquisitions, and the pharmaceutical industry, Chirag brings strong...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes it. Pharma manufactures it. The regulator approves it. But who ensures...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of marketing. It suffers from a shortage of trustworthy information patients...

The Great Healthcare Dilemma: Who Will Own the Next Indian Hospital?

The next owner of an Indian hospital may not be the doctor whose name is on the board. Institutional capital...

Indian Pharma’s Three Deficits—and Three Potential Dividends

Indian pharma has already done the hard thing once. It mastered chemistry, manufacturing scale, and generics—becoming indispensable to global healthcare....

Indian Pharma Is Two Industries Wearing One Label

Indian pharma is often discussed as one sector. In reality, the economics, operating models, and measures of success are...
spot_imgspot_img

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun Bhatia’s action against Glaxo’s Worli unit in 1993 to the...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical and healthcare industry, Shakul brings extensive expertise in vaccines, commercial...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to iron tablets. It is about whether those tablets ultimately translate...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of deal value, market share, synergies, and shareholder returns. But MedicinMan’s...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing the two turns a treatable protocol into a financial death...

A Tale of Two Cities: Peptides and Prescriptions

What our health choices reveal about education, access and inequality in India A cancelled “peptide party” in Bengaluru and a...